Having trouble viewing this email? View in your browser.
ESCMID Logo

15 January 2019
WEEKLY NEWS

Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,

ESCMID Executive Office.

 

ESCMID Postgraduate course on PK/PD, breakpoints and TDM

ESCMID and EPASG are pleased to announce the course ‘Optimised dosing of antibiotics – understanding PK/PD, clinical breakpoints and therapeutic drug monitoring’, to be held in Rotterdam, Netherlands on April 11 and 12.

A perfect way to complement your ECCMID experience! Register online here!

Attendance grants can be applied for until 30 January! 

› Read more
OPEN CALLS | APPLICATIONS

Registration for ECCMID 2019 - Early Bird fee until
24 January 2019

ECCMID is approaching soon!

To benefit from the early-bird registration deadline, please register before 24 January 2019. Make sure you use our official website to book your hotels to get the best rates.

› Read more

Diagnostic stewardship: are we using the right term?

The Executive Committees of the ESCMID Study Groups for Antimicrobial Stewardship (ESGAP) and for Genomic and Molecular Diagnostics (ESGMD) have recently discussed the use of the expression “Diagnostic stewardship” in CMI. They do not consider this term intuitive to non-experts and call for clearer terminology in the antimicrobial resistance field.

› Read more
 

CMI highlight: results of an open-label trial with a five-day oral antibiotics course preceding faecal microbiota transplantation

Huttner et al evaluated whether oral antibiotics followed by faecal microbiota transplantation (FMT) can eradicate intestinal carriage with extended spectrum beta-lactamase (ESBL-E) and carbapenemase-producing Enterobacteriaceae (CPE). In their randomized, open-label superiority trial, they enrolled 39 patients [tertiary care centres in Geneva n=14; Paris n=16; Utrecht n=7; Tel Aviv n=2], who were colonized by ESBL-E (n=36) and/or CPE (n=11). In the intention to treat analysis, 9/22 (41%) patients assigned to the intervention arm were negative for ESBL-E/CPE at 35-48 days after randomization (V4). In this arm, one of the 22 patients, not receiving the intervention, was imputed as positive. In the control arm, 5/17 (29%) patients were negative. One patient, lost to follow-up, was imputed as negative. The resulting odds ratio for decolonization success was 1.7 [95%CI 0.4-6.4]. Study drugs were overall well-tolerated. Three patients in the intervention group prematurely stopped the study antibiotics because of diarrhoea (all received FMT). Based on these findings the authors conclude that non-absorbable antibiotics followed by FMT slightly decreased ESBL/CPE carriage compared to controls. This difference was not statistically significant and potentially due to early trial-termination. Further clinical investigations seem warranted.

› Read more
 

E-Library highlight: Antimicrobial resistance from bench to practice

Did you miss the ESCMID conference on Antimicrobial resistance in Cuba last October? Catch up on the presentations on the ESCMID E-Library.

› Read more
 

ESCMID Funded Observership at the Mayo Clinic (USA): applications are being accepted from now until 31 January 2019.

Applications are now open for the ESCMID Funded Observership at the Mayo Clinic, Rochester (USA). You can apply for this special Observership until 31 January 12:00 (CET) by using this link.

So make sure you get your application to us before then. At the link you will also find more information and instructions on how to start the application process. This special observership cannot take place before May 2019, and should last between 2 and 4 weeks to allow the observer to make the most out of this opportunity. Please ensure that you have all the necessary documents to send with your application.

In case of any questions relating to this observership, or to ESCMID observership programmes in general, please contact: observership@escmid.org

The call for ESCMID funded observerships at all other ECCs will open in spring 2019.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Switzerland
Phone +41 61 5080 173
info@escmid.org
www.escmid.org
Follow ESCMID
Visit us on LinkedIn Visit us on YouTube
 
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.